Characteristic | EPAT (n = 127) | Â | WELL-HART (n = 105) | Â | Â | |||
---|---|---|---|---|---|---|---|---|
 | Placebo (n = 57) | ET (n = 70) | P | Placebo (n = 37) | ET (n = 34) | EPT (n = 34) | P* | P †|
Age at baseline mammogram, years (mean ± SEM) | 62.3 ± 1.0 | 60.2 ± 0.8 | 0.10 | 64.7 ± 1.0 | 61.8 ± 1.2 | 64.1 ± 1.1 | 0.15 | 0.005 |
Years since menopause at baseline (mean ± SEM) | 15.1 ± 1.4 | 12.5 ± 1.0 | 0.12 | 18.6 ± 1.6 | 15.9 ± 1.4 | 19.5 ± 1.9 | 0.28 | 0.001 |
Number of deliveries (live and stillbirths) (mean ± SEM) | 2.4 ± 0.2 | 2.3 ± 0.2 | 0.75 | 4.5 ± 0.6 | 3.6 ± 0.4 | 4.1 ± 0.5 | 0.47 | 0.0001 |
Race, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
White, non-latina | 34 (59.7) | 40 (57.1) | Â | 12 (32.4) | 7 (20.6) | 14 (41.2) | Â | Â |
Black, non-latina | 6 (10.5) | 10 (14.3) | Â | 4 (10.8) | 10 (29.4) | 5 (14.7) | Â | Â |
Latina | 10 (17.5) | 13 (18.6) | Â | 20 (54.1) | 9 (26.5) | 11 (32.4) | Â | Â |
Asian or Pacific Islander | 7 (12.3) | 7 (10.0) | 0.91 | 1 (2.7) | 8 (23.5) | 4 (11.8) | 0.01‡ | 0.0005 |
Education, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
High school graduate or less | 8 (14.0) | 9 (12.9) | Â | 20 (54.1) | 15 (44.1) | 15 (44.1) | Â | Â |
Trade or business school/some college | 29 (50.9) | 33 (48.6) | Â | 11 (29.7) | 12 (35.3) | 13 (38.2) | Â | Â |
Bachelor's degree or more | 20 (35.1) | 27 (38.6) | 0.92 | 6 (16.2) | 7 (20.6) | 6 (17.7) | 0.90 | 0.0001 |
Family history of breast cancer (first-degree relative), n (%) | 9 (15.8) | 6 (8.6) | 0.21 | 2 (5.4) | 7 (20.6) | 3 (8.8) | 0.14‡ | 0.91 |
Age at menarche, years (mean ± SEM) | 12.7 ± 0.2 | 12.6 ± 0.2 | 0.86 | 12.7 ± 0.3 | 12.8 ± 0.3 | 13.3 ± 0.3 | 0.32 | 0.21 |
Ever used postmenopausal hormones, n (%) | 36 (63.2) | 42 (60.0) | 0.72 | 13 (35.1) | 15 (44.1) | 21 (61.8) | 0.08 | 0.02 |
BMI, kg/m2 (mean ± SEM) | 28.7 ± 0.7 | 28.7 ± 0.7 | 0.96 | 30.8 ± 1.0 | 31.4 ± 1.0 | 30.2 ± 1.1 | 0.73 | 0.007 |
Mammographic density at baseline, % (mean ± SEM) | 17.8 ± 2.3 | 22.3 ± 1.9 | 0.13 | 7.9 ± 1.8 | 10.8 ± 2.1 | 13.3 ± 2.3 | 0.19 | 0.0001 |